Myopia is swiftly emerging as a global epidemic, posing a significant threat to long-term vision health. With projections indicating that 50% of the world's population will be affected by 20501, urgent action is essential to implement effective myopia control strategies, particularly among younger age groups where prevalence is on the rise. CooperVision assumes a pivotal role in combating the myopia epidemic by providing a suite of solutions designed to control myopia, rather than merely correcting it.
Myopia prevalence is at an alarming rate in East Asia:
Myopia is swiftly emerging as a global epidemic, posing a significant threat to long-term vision health. With projections indicating that 50% of the world's population will be affected by 20501, urgent action is essential to implement effective myopia control strategies, particularly among younger age groups where prevalence is on the rise. CooperVision assumes a pivotal role in combating the myopia epidemic by providing a suite of solutions designed to control myopia, rather than merely correcting it.
Myopia prevalence is at an alarming rate in East Asia:
Soft contact lenses have emerged as a popular option for myopia control, offering a convenient and effective alternative to traditional methods. Coopervision's MiSight® 1 day - the world's first US approved soft contact lens to slow the progression of myopia in children aged 8-12 years at the initiation of treatment.
Slows myopia progression by approximately 50%7
9/10 children between contact lens to spectacles8
Strong safety profile as they are 1-day lenses9
In Asia, clinics are progressively incorporating innovative interventions into their myopia control programs, offering patients a holistic approach to managing myopia. Ophthalmologists and Optometrists are pivotal in prescribing and overseeing these interventions, ensuring their effectiveness and safety. However, despite these strides, ECPs face challenges such as patient adherence, highlighting the importance of continuous education and support.
Despite challenges, the future of myopia control in Asia and across the globe looks promising, driven by technological advancements.
However, regulatory standards must evolve to ensure patient safety. Continued research and collaboration are essential in advancing myopia control practices and addressing the evolving needs of patients. CooperVision organizes the Asia-Pacific Myopia Management Symposium (APMMS) to support ECPs in fostering a collaborative environment, empowering them to address the urgency of myopia progression urgently. This annual gathering fosters the exchange of ideas and innovations crucial to combating the myopia epidemic.
Addressing the rising prevalence of myopia requires urgent action. By embracing innovation and enhancing clinical practices, we can effectively manage myopia and safeguard long-term vision health through awareness, accessibility, and research collaboration, building a brighter future for generations to come.
Contact Our Business Development Manager
